News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Protalix Biotherapeutics, Inc. Plans Human Clinical Tests of Medication for Rare Fabry’s Disease
March 24, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Protalix BioTherapeutics Ltd., an Israeli biotechnology company, plans to start clinical trials of a drug treating Fabry disease this year and a medication against rheumatoid arthritis in early 2012.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
MORE ON THIS TOPIC
Podcast
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
July 8, 2026
·
1 min read
·
Jef Akst
Obesity
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending
July 7, 2026
·
4 min read
·
Gabrielle Masson
Psychedelics
Compass’ psilocybin depression drug works for the long haul
July 7, 2026
·
2 min read
·
Annalee Armstrong
Cancer
BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial
July 7, 2026
·
2 min read
·
Tristan Manalac
